Subscribe

Differences in NSCLC Patient Populations

Videos - Lung Cancer
Edward Garon, MD
Dr. Edward Garon speaks about how differences in patient populations with lung cancer can make it difficult to interpret and act on data.
Related Items
Adjuvant Osimertinib a Practice-­ Changing Treatment in Early-Stage NSCLC with EGFR Mutation
Wayne Kuznar
August 2020 Vol 13, Special Issue published on August 17, 2020 in Lung Cancer
Durvalumab plus Chemotherapy New Standard of Care for Extensive-Stage Small-Cell Lung Cancer
Phoebe Starr
August 2020 Vol 13, Special Issue published on August 17, 2020 in Lung Cancer
Capmatinib Shows Activity in MET-Amplified Non–Small-Cell Lung Cancer
Wayne Kuznar
August 2020 Vol 13, Special Issue published on August 17, 2020 in Lung Cancer
Zepzelca New Therapy Approved for Metastatic Small-Cell Lung Cancer
Web Exclusives published on June 19, 2020 in FDA Approvals, Lung Cancer
FDA Approves Cyramza plus Tarceva for First-Line Treatment of Metastatic NSCLC with EGFR Mutation
Web Exclusives published on June 8, 2020 in FDA Approvals, Lung Cancer
Last modified: April 27, 2017
Copyright © Engage Healthcare Communications, LLC. All rights reserved.